Search

Your search keyword '"A. de Reyniès"' showing total 190 results

Search Constraints

Start Over You searched for: Author "A. de Reyniès" Remove constraint Author: "A. de Reyniès" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
190 results on '"A. de Reyniès"'

Search Results

1. PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up

2. Author Correction: Community assessment of methods to deconvolve cellular composition from bulk gene expression

3. Community assessment of methods to deconvolve cellular composition from bulk gene expression

4. Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation

5. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer

6. Community assessment of methods to deconvolve cellular composition from bulk gene expression

7. Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation

8. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer

9. Author Correction: Community assessment of methods to deconvolve cellular composition from bulk gene expression

10. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor–related Apoptosis-inducing Ligand in FGFR3-mutated Tumors

11. Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

12. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer

13. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer

14. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability

15. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)

16. Molecular and clinical diversity in primary central nervous system lymphoma

18. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer

19. Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials

20. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression

21. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

22. PrPCcontrols epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up

23. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)

24. A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer

25. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor–related Apoptosis-inducing Ligand in FGFR3-mutated Tumors

26. Abstract 5430: Improved colorectal cancer survival prediction with deep learning-based WSI analysis on PETACC8 and PRODIGE13 cohorts

27. De l'expressivité des éléments naturels : le Cours de peinture par principes de R.oger de Piles (1708).

28. Supplemental Table 1-3 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

29. Supplemental Figure 4-6 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

30. Supplemental Figure 7-10 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

31. Data from Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma

34. Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

35. Supplemental Figure Legends from Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity

36. Supplementary Figure and Tables legends from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

37. Supplementary Figure and Table Legends from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

38. Supplemental Table 7-10 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

39. Supplementary Table 4 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

40. Supplementary Figure S1 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

41. Supplementary Materials from Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity

42. Supplementary Table 2 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

43. Supplementary Table 2 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

44. Supplementary Table 5 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

45. Supplementary Table 3 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

46. Supplemental Figure 1-3 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

47. Supplementary Table 3 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

48. Supplementary Table S4 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

50. Supplementary Table 6 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

Catalog

Books, media, physical & digital resources